{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=44", "query": { "intervention": "Placebo- C", "page": 44 }, "page_size": 10 }, "pagination": { "page": 44, "page_size": 10, "total_count": 1834, "total_pages": 184, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=45&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=43&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T23:59:29.439Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03964415", "title": "A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Mos4.HIV", "type": "BIOLOGICAL" }, { "name": "Clade C and Mosaic gp140 HIV bivalent vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 3900, "start_date": "2019-10-31", "completion_date": "2023-08-10", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-28T23:59:29.439Z", "location_count": 20, "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03964415" }, { "nct_id": "NCT06225115", "title": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cognitive Dysfunction", "Schizophrenia" ], "interventions": [ { "name": "KYN-5356", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kynexis B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 72, "start_date": "2023-12-21", "completion_date": "2024-10-07", "has_results": false, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-10-28T23:59:29.439Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06225115" }, { "nct_id": "NCT05349214", "title": "Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sjogren Syndrome" ], "interventions": [ { "name": "VAY736", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 506, "start_date": "2022-08-04", "completion_date": "2027-04-15", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-28T23:59:29.439Z", "location_count": 23, "location_summary": "Fullerton, California • La Palma, California • Brandon, Florida + 19 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "La Palma", "state": "California" }, { "city": "Brandon", "state": "Florida" }, { "city": "Cooper City", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05349214" }, { "nct_id": "NCT01708278", "title": "Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Quercetin", "type": "DRUG" }, { "name": "Placebo - sugar chew", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 9, "start_date": "2014-02", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-12-26", "last_synced_at": "2026-10-28T23:59:29.439Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01708278" }, { "nct_id": "NCT07890376", "title": "A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "LY4086940", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 460, "start_date": "2026-11", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-28T23:59:29.439Z", "location_count": 39, "location_summary": "Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 35 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07890376" }, { "nct_id": "NCT02043587", "title": "Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphocytic Leukemia", "Adult Lymphoblastic Lymphoma" ], "interventions": [ { "name": "DNR", "type": "DRUG" }, { "name": "VCR", "type": "DRUG" }, { "name": "PEG-asp", "type": "DRUG" }, { "name": "CTX", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Liposomal AraC", "type": "DRUG" }, { "name": "MTX", "type": "DRUG" }, { "name": "LCV", "type": "DRUG" }, { "name": "AraC", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 31, "start_date": "2014-01", "completion_date": "2022-04-14", "has_results": false, "last_update_posted_date": "2022-05-02", "last_synced_at": "2026-10-28T23:59:29.439Z", "location_count": 4, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02043587" }, { "nct_id": "NCT02493452", "title": "Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Irritable Bowel Syndrome Characterized by Constipation" ], "interventions": [ { "name": "Plecanatide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 1135, "start_date": "2015-06", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2019-06-14", "last_synced_at": "2026-10-28T23:59:29.439Z", "location_count": 191, "location_summary": "Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 157 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Guntersville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02493452" }, { "nct_id": "NCT07570147", "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "ABBV-1451", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 90, "start_date": "2026-05-01", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-28T23:59:29.439Z", "location_count": 1, "location_summary": "Grayslake, Illinois", "locations": [ { "city": "Grayslake", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07570147" }, { "nct_id": "NCT06578247", "title": "Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Quizartinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 700, "start_date": "2024-11-19", "completion_date": "2030-06-26", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-28T23:59:29.439Z", "location_count": 52, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06578247" }, { "nct_id": "NCT03371355", "title": "Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NAFLD", "Diabetes Mellitus, Type 2", "Hypertriglyceridemia", "Fatty Liver, Nonalcoholic" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "ISIS 703802 40 mg", "type": "DRUG" }, { "name": "ISIS 703802 80 mg", "type": "DRUG" }, { "name": "ISIS 703802 20 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akcea Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 105, "start_date": "2017-12-21", "completion_date": "2020-02-24", "has_results": true, "last_update_posted_date": "2021-02-01", "last_synced_at": "2026-10-28T23:59:29.439Z", "location_count": 38, "location_summary": "Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fountain Hills", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03371355" } ] }